Karl-Christian Bergmann Selected Research

mepolizumab

2/2023	A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics.
10/2022	Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma.
8/2022	Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karl-Christian Bergmann Research Topics

Disease

21	Hypersensitivity (Allergy) 05/2024 - 01/2008
20	Asthma (Bronchial Asthma) 05/2024 - 01/2004
9	Allergic Rhinitis 05/2024 - 06/2014
9	Seasonal Allergic Rhinitis (Hay Fever) 03/2022 - 02/2002
4	COVID-19 01/2021 - 01/2020
2	Inflammation (Inflammations) 12/2023 - 01/2015
2	Atopic Dermatitis (Atopic Eczema) 09/2023 - 02/2013
2	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2021 - 10/2018
2	Anaphylaxis (Anaphylactic Shock) 01/2021 - 01/2014
2	Infections 01/2021 - 01/2017
1	AIDS-Related Complex (ARC) 01/2024
1	Symptom Flare Up 01/2024
1	Anosmia 02/2023
1	Eosinophilia 08/2022
1	Respiratory Insufficiency (Respiratory Failure) 08/2022
1	Angioedema 01/2022
1	Food Hypersensitivity (Food Allergy) 08/2021
1	Nasal Polyps (Nasal Polyp) 01/2021
1	Bacterial Infections (Bacterial Infection) 01/2021
1	Rhinosinusitis 01/2021
1	Neurodermatitis (Lichen Simplex Chronicus) 01/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Dysbiosis 01/2021
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 11/2019
1	Rhinitis 11/2019
1	Aspergillosis 01/2017
1	Urticaria (Hives) 02/2013
1	Drug Hypersensitivity (Drug Allergy) 02/2013

Drug/Important Bio-Agent (IBA)

16	AllergensIBA 01/2024 - 01/2008
4	Omalizumab (Xolair)FDA Link 08/2022 - 02/2002
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2004
3	Monoclonal AntibodiesIBA 12/2023 - 01/2020
3	mepolizumabIBA 02/2023 - 08/2022
3	TabletsIBA 03/2022 - 06/2014
3	VaccinesIBA 01/2021 - 01/2008
2	Biomarkers (Surrogate Marker)IBA 05/2024 - 12/2023
2	Air Pollutants (Pollutants, Air)IBA 09/2023 - 03/2020
2	benralizumabIBA 02/2023 - 08/2022
2	Proteins (Proteins, Gene)FDA Link 07/2022 - 01/2020
2	Environmental Pollutants (Pollutants, Environmental)IBA 03/2020 - 04/2017
2	Immunoglobulin E (IgE)IBA 10/2018 - 02/2013
2	ragweed pollenIBA 01/2018 - 01/2014
1	Lactoglobulins (beta-Lactoglobulin)FDA Link 07/2023
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 01/2022
1	Interleukin-17 ReceptorsIBA 08/2021
1	Interleukin-17 (Interleukin 17)IBA 08/2021
1	COVID-19 VaccinesIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	PrebioticsIBA 01/2021
1	AntibodiesIBA 01/2020
1	ImmunosorbentsIBA 01/2020
1	Interleukin-5 (Interleukin 5)IBA 01/2020
1	EnzymesIBA 01/2020
1	reslizumabIBA 11/2019
1	Environmental BiomarkersIBA 10/2019
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2014
1	ReaginsIBA 01/2014
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2014
1	GasesIBA 01/2014
1	EpitopesIBA 05/2008
1	PropionatesIBA 01/2004
1	Fluticasone (Cutivate)FDA LinkGeneric 01/2004
1	Beclomethasone (Beclometasone)FDA Link 01/2004
1	Salmeterol Xinafoate (Serevent)FDA Link 01/2004
1	anti-IgE antibodiesIBA 02/2002

Therapy/Procedure

12	Therapeutics 12/2023 - 01/2004
5	Immunotherapy 01/2019 - 02/2002
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2016
1	Withholding Treatment 10/2022
1	Injections 10/2022
1	Transplantation 08/2022
1	Biological Therapy 01/2021
1	Dry Powder Inhalers 01/2004